☆ 4.7 Article

Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

PHARMACEUTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE

Wenjia Zhu et al.

Summary: This study evaluated the diagnostic efficacy of (68) Ga-NODAGA-LM3 and (68) Ga-DOTA-LM3 compared to (68) Ga-DOTATATE in patients with neuroendocrine tumors. Both (68) Ga-NODAGA-LM3 and (68) Ga-DOTA-LM3 showed superiority in lesion detection and tumor uptake compared to (68) Ga-DOTATATE, demonstrating their potential as promising SSTR2 antagonists for neuroendocrine tumors.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Chemistry, Medicinal

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates

Melpomeni Fani et al.

Summary: Recently, radiolabelled antagonists targeting somatostatin receptors subtype 2 (SST2) in neuroendocrine neoplasms demonstrated certain superior properties over agonists. Within the ERA-PerMED project TECANT two Tc-99m-Tetramine (N4)-derivatized SST2 antagonists (TECANT-1 and TECANT-2) were studied for the selection of the best candidate for clinical translation. The preclinical study provided the basis of selection of [Tc-99m]Tc-TECANT-1 for clinical translation of the first Tc-99m-based SST2 antagonist.

PHARMACEUTICALS (2021)

添加到收藏夹

Review Oncology

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Valentina Ambrosini et al.

Summary: Nuclear medicine plays a crucial role in managing neuroendocrine neoplasms, using techniques such as peptide receptor radionuclide therapy and positron emission tomography. Recommendations from the European Association of Nuclear Medicine provide valuable guidance for the diagnosis and treatment of NETs.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors

Wenjia Zhu et al.

Summary: This study evaluated the safety, biodistribution, and dosimetry of Ga-68-NODAGA-LM3 and Ga-68-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors. Results showed favorable biodistribution, high tumor uptake, and good tumor retention for both tracers, with comparable dosimetric data to other Ga-68-labeled SSTR2 antagonists. Further studies are needed to explore the potential antagonistic effects of Ga-68-NODAGA-LM3 and Ga-68-DOTA-LM3.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Chemistry, Medicinal

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE

Rosalba Mansi et al.

Summary: Comparing the binding kinetics and cellular mechanisms of [Lu-177]Lu-OPS201 and [Lu-177]Lu-DOTA-TATE, the study found that [Lu-177]Lu-OPS201 recognized more receptor binding sites, with faster association and slower dissociation, explaining the improved therapeutic efficacy of [Lu-177]Lu-OPS201 compared to [Lu-177]Lu-DOTA-TATE.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Chemistry, Medicinal

SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers

Raghuvir Haridas Gaonkar et al.

Summary: [Tc-99m]Tc-HYNIC-TOC is a commonly used radiotracer for SST-expressing tumors, but recent studies have shown that Tc-99m-labeled SST antagonists may have better diagnostic efficacy. Different spacers were investigated to improve the affinity of HYNIC conjugates with SST2 antagonists. The use of Ahx as a spacer significantly improved the cellular uptake of the conjugates, demonstrating its potential for imaging agents.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Chemistry, Medicinal

EANM guideline on the validation of analytical methods for radiopharmaceuticals

Nic Gillings et al.

EJNMMI RADIOPHARMACY AND CHEMISTRY (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Thomas A. Hope et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study

Guillaume P. Nicolas et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

Keelara Abiraj et al.

EJNMMI RESEARCH (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA

Murat Fani Bozkurt et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

Damian Wild et al.

JOURNAL OF NUCLEAR MEDICINE (2014)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments

Sander M. Bison et al.

CLINICAL AND TRANSLATIONAL IMAGING (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

Damian Wild et al.

JOURNAL OF NUCLEAR MEDICINE (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

Mihaela Ginj et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

[99mTc]demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours:: synthesis and preclinical results

T Maina et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.